Login / Signup

Autoimmune polyendocrine syndrome type 3, characterized by autoimmune thyroid disease, type 1 diabetes mellitus, and isolated ACTH deficiency, developed during adjuvant nivolumab treatment.

Mayumi TakataMotoo NomuraKentaro YamamuraManabu MutoTakaya KomoriAtsushi OtsukaKenji Kabashima
Published in: Asia-Pacific journal of clinical oncology (2021)
Autoimmune polyendocrine syndrome (APS) is one of the life-threatening immune-related adverse events (irAEs). We firstly report a case of APS induced by adjuvant nivolumab therapy. Clinicians should be aware of the potential risks of developing severe irAEs when applying adjuvant immunotherapy.
Keyphrases
  • early stage
  • multiple sclerosis
  • drug induced
  • case report
  • human health
  • cardiovascular disease
  • glycemic control
  • cardiovascular risk factors
  • combination therapy